Article Details

China approves Merck's covid therapy amid shortage of drugs - The Spokesman-Review

Retrieved on: 2022-12-31 08:26:38

Tags for this article:

Click the tags to see associated articles and topics

China approves Merck's covid therapy amid shortage of drugs - The Spokesman-Review. View article details on hiswai:

Excerpt

It's the second foreign COVID-19 treatment cleared for use in China after authorities gave Pfizer's Paxlovid the go-ahead in early 2022.

Article found on: www.spokesman.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up